Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
MBX Biosciences $200 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Laekna HK$587 million placement of shares
We advised Laekna on the placement of new shares
Strive acquisition of Semler Scientific
We are advising Strive on the acquisition
Oruka Therapeutics $180 million private placement
The PIPE included common stock and pre-funded warrants
GenFleet Therapeutics HK$1.82 billion IPO
We advised GenFleet on its IPO and HKEX listing
Oscar Health $410 million convertible senior subordinated notes and capped call transactions
The 2.25% convertible notes are due 2030
Royalty Pharma $2 billion senior notes offering
We advised Royalty Pharma on its investment-grade notes offering
Elevance Health $3 billion senior notes offering
The investment-grade notes are due 2028, 2032, 2036 and 2055
Alnylam Pharmaceuticals $661.25 million convertible senior notes offering
The 0% convertible notes are due 2028
Maze Therapeutics $150 million private placement
The PIPE included common stock and pre-funded warrants